do a search if interested
Ummmm.....anon. That's not usually how we spread info on this forum...but okay. Here's the results of the "search" I did and the results don't really comport with your sensational title which I presume you got from a sensation 2018 study that has been addressed.
Here's the link: https://www.jaad.org/article/S0190-9622(18)32469-1/fulltext
Here's what the report in the Journal of the American Academy of Dermatology, Jan 2019 said:
Aspirin use and the risk of malignant melanoma By: Lichtenberger and Burge
To the Editor: “Daily aspirin dose ‘doubles risk of skin cancer in men,’” reported the Daily Telegraph.1 A Google search for “aspirin and melanoma” in June 2018 yielded several similar links from news outlets and medical trade publications, all pointing to an article in press by Orrell et al2 that was recently published in the Journal. Are these alarming headlines justified by the study?
Orrell et al2 found an adjusted relative risk of malignant melanoma of 1.83 in aspirin-exposed men; the adjusted risk was 0.53 for women but was not statistically significant. This study's methodology has substantial weaknesses. The exposed population was selected based on a documented aspirin prescription, while the unexposed population included other adults in the system without a history of melanoma. This method avoids self-reported exposure but causes confounding by indication. Aspirin prophylaxis is indicated for older patients with increased cardiovascular disease risk. Indeed, the exposed group was 15 years older, on average, than the unexposed group. Although the researchers controlled for age, regression alone does not adequately account for additional comorbidities implied by a prescription, especially when the groups differ greatly at baseline. In addition, an aging, high-risk subpopulation is likely to interact with the health system more often, leading to surveillance bias.
Despite the large cohort (66,134 men), relatively few aspirin users were identified (664, or 1% of men). Only 26 melanoma cases (23 men) were reported among aspirin users, compared with 1675 cases (670 men) in the unexposed group. Attributing this extreme gender skew entirely to aspirin strains credulity, particularly considering the small sample size. Even more concerning, many patients were almost certainly misclassified: <1% of the sample was counted as aspirin-exposed, but over half of US adults 45 to 75 years of age report taking aspirin regularly.3 The prescription rate in this study is also far lower than clinical guidelines predict, but this is unsurprising because verbal recommendations often go undocumented. Prescriptions for over-the-counter medications may be needed for payment by Medicaid and other insurers, or at hospitals and long-term care facilities. Therefore, the selection criteria may well have captured the sickest and poorest subset of aspirin users.
As the authors note, this finding disagrees with previous results. Three studies, including 1 randomized trial, showed no effect of aspirin on melanoma risk, while 5 studies showed a statistically significant preventive benefit of aspirin; 1 study found increased melanoma risk in women, but no dose–response relationship.4 In our review of the literature, there is compelling evidence from metaanalyses of numerous large randomized trials showing reduced cancer incidence among aspirin users. The effect held for as many as 12 types of cancer, suggesting a common mechanism of action.5 The US Preventive Services Task Force now recommends aspirin for colorectal cancer prevention in most patients over 55 years of age.
In light of this study's limitations, the best evidence does not support aspirin as a risk factor for any cancer, including melanoma. Most clinicians would likely agree. Will laypeople, seeing the current spate of news articles, reach the same conclusion?
In addition, there are many reports indicating a beneficial effect from NSAID's (that includes aspirin) in preventing cancer and facilitating the action of immunotherapy. Here are numerous reports:
2016 and prior: https://chaoticallypreciselifeloveandmelanoma.blogspot.com/2016/08/soooa...
All that being said....we have no absolutes one way or another. I think that an aspirin regimen should be started or stopped only after a serious discussion with ones doctor and if on any treatment for melanoma, one would be wise to share all meds the patient is taking with the prescribing oncologist...even if it is "just" an over the counter drug.
For what it's worth. Celeste
Thank you, Celeste!
October 2017 primary scalp WLE; SLNB; partial neck dissection (PND). July 2018 recurrence in neck. August 2018 second PND. September 2018 started Nivo. December 2018 SRS for brain met January 2019 Pisces trial IL-12 + Pembro. .
Doesnt sound possible....
Melanoma Will Not Beat Me or my MRF Family!www.wespark.orgwww.covvha.net
FYI ,When my mom was diagnosed Nov 2018 , she was enrolled into a trial at UCSF which included ( nivo/ipi + High strength Aspirin). Her mel specialist is Dr. Adil Daud and the trial is still in progress.
As you know sis, some folks especially "some" not all, of the Anonymouses we have here, will post the most absurd, false findings one could ever dream of making up or providing a link of someone elses poor data. Its like me telling you guys that Melanoma has been now linked to years and years of licking envolopes & stamps & that the sticky solution that adheres causes changes to ones melancytes & wahLah! A lesion is born....pishposh! Tom Foolery! Their board thats all...
Still learning that Mike, Hope you are feeling fine after the triple combo
Every hour one American dies from melanoma.
Donate what you can
Your donation can save lives. Thank you!
Your tax-deductible donation can make a difference.